散结镇痛胶囊联合米非司酮治疗子宫内膜异位症的临床分析

目的:评价散结镇痛胶囊联合米非司酮治疗子宫内膜异位症的疗效和安全性。方法:44例诊断为子宫内膜异位症患者随机分成两组,对照组16例给予米非司酮12.5mg口服,1次/d,于月经来潮第一天开始用,连用六个月经周期。治疗组28例在对照组基础上同时给予散结镇痛胶囊口服,4粒/次,3次/d,也于月经来潮第一天开始用,连用六个月经周期。两组均在治疗六个月后复查,比较两组治疗子宫内膜异位症的疗效和不良反应情况。结果:治疗组痛经、非经期下腹痛、性交痛、后陷凹结节、肛门坠痛的改善率与对照组比较,差异有统计学意义(P<0.05)。两组治疗后的阴道异常出血、体重增加、转氨酶升高及皮肤改变等不良反应发生率比较(P<0.05)差异有统计学意义。结论:散结镇痛胶囊联合米非司酮治疗子宫内膜异位症较单独使用米非司酮效果好,不良反应少,安全性高,适于临床广泛使用。

A clinical analysis of treating endometriosis with Sanjie Zhentong capsule plus mifepristone

Objective：To evaluate efficacy and safety of Sanjie Zhentong capsule plus mifepristone for endometriosis. Methods：44 patients diagnosed with endometriosis were randomly divided into 2 groups; in control group 16 cases were given 12.5mg oral mifepristone. In treatment group 28 cases were given Sanjie Zhentong capsule more. Results：In treatment group dysmenorrhea, menstrual period abdominal pain, pain during sex, pouch after nodules, anal pain of period compared with control group, the difference was statistically significant （P＆lt;0.05）. Two groups after treatment of abnormal vaginal bleeding, weight gain, elevated aminotransferase and the skin change incidence of adverse reactions and compared （P＆lt;0.05） difference was statistically significant. Conclusion： Sanjie Zhentong capsule plus mifepristone for endometriosist is better, less adverse reaction, high safety, suitable for clinical use.